Abstract
It seems that, with the anticipation of a new millennium, there is keen interest in predicting what is likely to happen in almost every human endeavor once that boundary has been crossed, and the future of breast cancer research is no exception. At the request of the organizers of the February 1998 meeting of the International Congress on Anti-Cancer Therapy in Paris, I undertook the daunting, if not impossible, task of presenting a commentary on “the future of breast cancer research.” This commentary is based primarily upon my presentation at the Paris meeting; it deals with the importance of understanding how current breast cancer management concepts were derived from past research and how the immediate future of brewit cancer research and treatment will be related to present findings. Because unknown events that occur in the immediate future are apt to shape the more distant future, long-range speculation is of limited value. In that regard, it needs to be emphasized that it is not in the best interest of either physicians or their patients to fecus exclusively on the future and disregard recent advances in the understanding and treatment of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fisher B: Laboratory and clinical research in breast cancer — A personal adventure: The David A. Kamofsky Memorial Lecture. Cancer Research 40:3863–3874, 1980
Fisher B: The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Research 52:2371–2383, 1992
Fisher B: Personal contributions to progress in breast cancer research and treatment. Seminars in Oncology 23:414–427, 1996
Root-Bernstein RS: Discovering. Harvard University Press, Cambridge, MA, 1989, p. 501
Kuhn TS: The Structure of Scientific Revolutions, ed. 2. Chicago, University of Chicago Press, 1970
Silverman WA: Where’s the Evidence? Controversies in Modem Medicine. Oxford University Press, Oxford, 1998, Chapter 24, p. 98, pps. 259
Thomas L: Quoted in: Redmond C and Fisher B: Design of the controlled clinical trial. In: Yosef H. Pilch, Tapas Das Gupta, eds. Surgical oncology. New York, New York. McGraw Mill Book Company, 1994
Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. NEngl. r Med 312:674–681, 1985
National Surgical Adjuvant Breast and Bowel Project: NSABP Progress Report. 1997, pp. 17–23
Fisher B, Anderson S, Redmond C, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:14561461, 1995
Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer o the breast: Results of a decade of cooperative investigation.Ann Surg 168:337–356, 1968
Fisher B, Carbone P, Economou SG, et al: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117–122, 1975
Bonadonna G, Brusamolino, E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410, 1976
Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen.N Engl J Med 305:1–6, 1981
Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4:459–471, 1986
Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484, 1989
Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node negative, estrogen receptor-positive, breast cancer, J Natl Cancer Inst 89:1673–1682, 1997
Fisher B, Costantino J, Redmond C, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581–1586, 1993
Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452, 1998
Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: Findings from National Surg Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493, 1997
Fisher B, Bryant J, Wolrnark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685, 1998
Fisher B, Mamounas EP: Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13:537–540, 1995
Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371–1388, 1998
Bulletin: American Association of Retired People. AARP, 1998, p. 10
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag France
About this paper
Cite this paper
Fisher, B. (1999). A Personal Perspective About the Future of Breast Cancer Research and Treatment. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_3
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0918-2_3
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-59666-7
Online ISBN: 978-2-8178-0918-2
eBook Packages: Springer Book Archive